Los Angeles Software Firm Rwazi Raises $12 Million Series A Round
'For decades, decisions have been driven by instinct. But gut calls are expensive and in today's market, they're dangerous,' said Joseph Rutakangwa, chief executive and co-founder of Rwazi, in a statement. 'This raise lets us put a real-time AI copilot in the hands of every decision-maker so teams can move faster, smarter and with total clarity.'
Rwazi captures real-time consumer activity shared directly and voluntarily at a massive scale. That precision powers a new kind of intelligence system that helps teams detect shifts early, simulate outcomes, and act with speed and confidence.
The system receives constant data. The company already analyzes billions of behavioral signals across demographics, markets and products. The funding will be used to expand Rwazi's simulation capabilities, global data infrastructure and enhance its AI copilot's ability to contextualize and recommend next best moves across functions.
Information for this article was sourced from Rwazi.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
CorriXR Therapeutics Secures $1M Investment from State of Delaware
NEWARK, Del., August 19, 2025--(BUSINESS WIRE)--CorriXR Therapeutics, Inc., a pioneering oncology-focused biotherapeutics company, has announced a significant milestone with a $1M investment from the State of Delaware. This funding will be instrumental in advancing CorriXR's lead program aimed at developing next-generation treatments for solid tumors, with particular focus on head and neck, and lung cancers. This investment not only underscores the potential of CorriXR's cutting-edge therapies but also highlights Delaware's commitment to supporting innovative early-stage companies. "We're excited to have the State of Delaware participate in our Series A financing round as we advance toward our first-in-human clinical trial," said Eric Kmiec, Ph.D., founder & CEO of CorriXR. "This investment will be critical as we complete preclinical studies, scale-up manufacturing, and prepare our investigational new drug (IND) submission." The State of Delaware's investment in CorriXR is the first $1M investment from the Delaware Accelerator & Seed Capital Program (DASCP), one of four programs awarded under the State Small Business Credit Initiative (SSBCI) federal program from the U.S. Treasury Department. The Division of Small Business is administering Delaware's $60.9 million SSBCI award aimed at providing access to capital for start-up and early-stage businesses. "Our first $1 million investment is proof that Delaware's path to becoming the Mid-Atlantic hub for Innovation is well underway," said Delaware Division of Small Business Director CJ Bell. "Supporting companies like CorriXR to scale isn't just good business – it's the blueprint for turning that vision into reality." "This is how Delaware wins the future, with CorriXR demonstrating the power of turning research into real solutions," said Delaware Governor Matt Meyer. "By working closely with experts at the Gene Editing Institute, CorriXR is making promising CRISPR therapies a reality for patients faster than ever. This is exactly why the SSBCI program exists—because supporting innovation today means better treatments, stronger businesses, and a brighter future for Delaware." About CorriXR Therapeutics CorriXR is developing genetic medicines to transform the treatment of solid tumors. CorriXR's patented non-viral gene editing tool disables transcription factor NRF2, which controls 200+ genes responsible for creating a pro-oncogenic tumor microenvironment. Knockout of NRF2 disrupts cancer cell survival mechanisms and sensitizes them to standard of care, and is being developed as a monotherapy, neoadjuvant or in combination with chemotherapy, radiotherapy, or immunotherapy. CorriXR's platform has potential applications in over 30 types of squamous cell carcinomas by improving treatment efficiency at lower doses, increasing patient eligibility, and reducing dropouts due to side effects—ultimately leading to improved patient outcomes. Learn more at View source version on Contacts Jennifer Kmiecjkmiec@ 302-689-3032 Sign in to access your portfolio
Yahoo
a day ago
- Yahoo
CorriXR Therapeutics Secures $1M Investment from State of Delaware
NEWARK, Del., August 19, 2025--(BUSINESS WIRE)--CorriXR Therapeutics, Inc., a pioneering oncology-focused biotherapeutics company, has announced a significant milestone with a $1M investment from the State of Delaware. This funding will be instrumental in advancing CorriXR's lead program aimed at developing next-generation treatments for solid tumors, with particular focus on head and neck, and lung cancers. This investment not only underscores the potential of CorriXR's cutting-edge therapies but also highlights Delaware's commitment to supporting innovative early-stage companies. "We're excited to have the State of Delaware participate in our Series A financing round as we advance toward our first-in-human clinical trial," said Eric Kmiec, Ph.D., founder & CEO of CorriXR. "This investment will be critical as we complete preclinical studies, scale-up manufacturing, and prepare our investigational new drug (IND) submission." The State of Delaware's investment in CorriXR is the first $1M investment from the Delaware Accelerator & Seed Capital Program (DASCP), one of four programs awarded under the State Small Business Credit Initiative (SSBCI) federal program from the U.S. Treasury Department. The Division of Small Business is administering Delaware's $60.9 million SSBCI award aimed at providing access to capital for start-up and early-stage businesses. "Our first $1 million investment is proof that Delaware's path to becoming the Mid-Atlantic hub for Innovation is well underway," said Delaware Division of Small Business Director CJ Bell. "Supporting companies like CorriXR to scale isn't just good business – it's the blueprint for turning that vision into reality." "This is how Delaware wins the future, with CorriXR demonstrating the power of turning research into real solutions," said Delaware Governor Matt Meyer. "By working closely with experts at the Gene Editing Institute, CorriXR is making promising CRISPR therapies a reality for patients faster than ever. This is exactly why the SSBCI program exists—because supporting innovation today means better treatments, stronger businesses, and a brighter future for Delaware." About CorriXR Therapeutics CorriXR is developing genetic medicines to transform the treatment of solid tumors. CorriXR's patented non-viral gene editing tool disables transcription factor NRF2, which controls 200+ genes responsible for creating a pro-oncogenic tumor microenvironment. Knockout of NRF2 disrupts cancer cell survival mechanisms and sensitizes them to standard of care, and is being developed as a monotherapy, neoadjuvant or in combination with chemotherapy, radiotherapy, or immunotherapy. CorriXR's platform has potential applications in over 30 types of squamous cell carcinomas by improving treatment efficiency at lower doses, increasing patient eligibility, and reducing dropouts due to side effects—ultimately leading to improved patient outcomes. Learn more at View source version on Contacts Jennifer Kmiecjkmiec@ 302-689-3032
TechCrunch
a day ago
- TechCrunch
AI crawler Firecrawl raises $14.5M, is still looking to hire agents as employees
Firecrawl's co-founder and CEO Caleb Peffer knew the exact moment he found the investor to lead his Series A. He was in a coffee meeting with Nexus Venture Partner's Abhishek Sharma at the Blue Bottle in San Francisco's South Park (a favorite VC haunt). While describing the future of the company, he was gesturing so animatedly that his chair tipped over. 'I actually fell out of my chair. And Abhishek, as a great Investor does, caught the chair and me as I was falling,' Peffer described with a laugh. That felt like a symbol for how the founder/investor relationship is supposed to work. 'I think that was a clear signal that he was the right partner.' On Tuesday, Firecrawl announced a Series A led by Nexus with participation from Shopify CEO Tobias Lütke and existing investor Y Combinator. Firecrawl offers a popular open-source web crawler for developers and AI agents, with a commercially supported version available through API. It's used by 350,000 developers, has nearly 50,000 stars on GitHub and its notable customers include Shopify, Replit, and Zapier as well as 'some of the largest hedge funds in the world,' Peffer told TechCrunch. And, he says, the company is already profitable. The startup also just released an API that supports search and will soon add support for natural language prompts, as co-founder and CTO Nicolas Silberstein Camara noted. Peffer, who co-founded Firecrawl in 2022 with Camara and CMO Eric Ciarla, said gaining Lütke as an investor was 'the best kind of validation.' Techcrunch event Tech and VC heavyweights join the Disrupt 2025 agenda Netflix, ElevenLabs, Wayve, Sequoia Capital, Elad Gil — just a few of the heavy hitters joining the Disrupt 2025 agenda. They're here to deliver the insights that fuel startup growth and sharpen your edge. Don't miss the 20th anniversary of TechCrunch Disrupt, and a chance to learn from the top voices in tech — grab your ticket now and save up to $600+ before prices rise. Tech and VC heavyweights join the Disrupt 2025 agenda Netflix, ElevenLabs, Wayve, Sequoia Capital — just a few of the heavy hitters joining the Disrupt 2025 agenda. They're here to deliver the insights that fuel startup growth and sharpen your edge. Don't miss the 20th anniversary of TechCrunch Disrupt, and a chance to learn from the top voices in tech — grab your ticket now and save up to $675 before prices rise. San Francisco | REGISTER NOW They landed him through a gutsy email after discovering the Shopify founder had signed up to try their product through their self-service portal. 'We saw his email come in,' Peffer said. The Firecrawl crew immediately emailed him to welcome him as a customer, but got no response. Two months later, some Shopify folks contacted Firecrawl for an enterprise contract. So Peffer took his shot and emailed Lütke again, mentioning they'd love for him to participate in their upcoming round. This time, Lütke responded with compliments about their product. He was in. While AI web crawlers have a somewhat dubious reputation these days, mostly due to bad actors that ignore files, they are also a necessary part of the burgeoning AI world. AI trains on the web, agents need to access web pages to perform their duties, and enterprises need personalized crawlers to consume their own websites for training and operations. The Firecrawl founders also hope to help address the frustrating parts of their industry. They are working on tools to help website owners, publishers, and other content creators 'get paid when AI uses their content. We think this is the way it should be,' Peffer said. While there have been lots of efforts around this idea from big names like Adobe and Getty as well as startups like Bria, Calliope Networks, and others, Peffer feels that Firecrawl has an edge because it's already working with those who are scraping data. 'We already have one side of the marketplace,' he said. 'What we want to do is just connect that side of the marketplace to the website owners, the publishers.' Interestingly, Firecrawl also went viral a few months ago for reasons that have little to do with their open source tool. They had posted an ad to the YC job board looking to hire an AI agent as an employee for a $15,000 salary – perhaps the first job ad for an agent employee, ever. That job search didn't yield an agent worth hiring, so Firecrawled upped the budget to up $1 million to hire several agents and the developers who built them, and tried again. Applicants flooded in, Peffer said, but the company hasn't yet hired any. The founders realized that evaluating and managing wanna-be agent employees is a job in itself. So now they are looking for an AI chief of staff. Firecrawl's Peffer will be on stage at Disrupt in October to discuss all that he's learned in a session that covers the pros and cons of hiring AI agents as early employees.
